References
- Allen J, Rosen G, Juergens H, Mehta B. The inability of oral leucovorin to elevate CSF 5-methyl-tetrahydrofolate following high dose intravenous methotrexate therapy. Journal of Neuro-Oncology 1983; 1: 39–44
- Aparicio A, Chamberlain M C. Neoplastic meningitis. Current Neurological Neuroscience Report 2002; 2: 225–235
- Bagshawe K D, Sharma S K, Southall P J, Boden J A, Boxer G M, Patridge T A, Antoniw P, Pedley R B. Selective uptake of toxic nucleoside (125IUdR) by resistant cancer. British Journal of Radiology 1991; 64: 37–44
- Bodei L, Kassis A I, Adelstein S J, Mariani G. Radionuclide therapy with iodine-125 and other Auger-electron-emitting radionuclides: Experimental models and clinical applications. Cancer Biotherapy & Radiopharmaceuticals 2003; 18: 861–877
- Kassis A I, Adelsten S J. Preclinical animal studies with radioiododeoxyuridine. Journal of Nuclear Medicine 1996; 37(4 suppl.)10S–12S
- Kassis A I, Dahman B A, Adelstein S J. In vivo therapy of neoplastic meningitis with methotrexate and 5-[125I]iodo-2′-deoxyuridine. Acta Oncologica 2000; 39: 731–737
- Kassis A I, Kirichian A M, Wang K, Safaie Semnani E, Adelstein S J. Therapeutic potential of 5-[125I]iodo-2′-deoxyuridine and methotrexate in the treatment of advanced neoplastic meningitis. International Journal of Radiation Biology 2004; 80: 941–946
- Mehta B M, Glass J P, Shapiro W R. Serum and cerebrospinal fluid distribution of 5-methyltetrahydrofolate after intravenous calcium leucovorin and intra-Ommaya methotrexate administration in patients with meningeal carcinomatosis. Cancer Research 1983; 43: 435–438
- Morgan J R, Jr, Newman E M, Doroshow J H, McGonigle K, Margolin K, Raschko J, Chow W, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Carroll M, Vasilev S, Akman S, Coluzzi P, Wagman L, Longmate J, Paz B, Yen Y, Klevecz R. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: Flow cytometric and pharmacokinetic analysis. Cancer Research 1998; 58: 2793–2800
- Ongerboer de Visser B W, Somers R, Nooyen W H, van Heerde P, Hart A A, McVie J G. Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 1983; 33: 1565–1572
- Sahu S K, Wen P YC, Foulon C F, Nagel J S, Black P M, Adelstein S J, Kassis A I. Intrathecal 5-[125I]iodo-2′-deoxyuridine in a rat model of leptomeningeal metastases. Journal of Nuclear Medicine 1997; 38: 386–390
- Sondak V K, Robertson J M, Sussman J J, Saran P A, Chang A E, Lawrence T S. Preoperative idoxuridine and radiation for large soft tissue sarcomas: Clinical results with five-year follow-up. Annals of Surgical Oncology 1998; 5: 106–112
- Urtasun R C, Kinsella T J, Farnan N, DelRowe J D, Lester S G, Fulton D S. Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: Final report of RTOG 86-12, Phase I–II study. International Journal of Radiation Oncology, Biology, Physics 1996; 36: 1163–1167
- Vokes E E, Dolan M E, Krishnasamy S, Mick R, Ratain M J, Berezin F, Brachman D, Whitman G, Schilsky R L, Charette J, Weichselbaum R R, Dohrmann G J, Hekmatpanah J. 5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for maglignant gliomas: A clinical and pharmacologic analysis. Annals of Oncology 1993; 4: 591–595
- Wang K, Adelstein S J, Kassis A I. DMSO increases radioiodination yield of radiopharmaceuticals. Applied Radiation and Isotopes 2008; 66: 50–59
- Wasserstrom W R, Glass J P, Posner J B. Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients. Cancer 1982; 49: 759–772